Pay in 4 interest-free payments of $7.02 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
At BEAUX MedSpa, BPC-157 is offered as part of our advanced peptide therapy in Austin, where patients often explore it for recovery, mobility support, and overall resilience
Xylo Research Systems LLC, dba Panda Peptides, is not a compounding pharmacy or chemical compounding facility as defined under 503A of the Federal Food, Drug, and Cosmetic act
This service involves administering vitamin B12 directly into the muscle, allowing for better absorption vs oral supplements
GHK-Cu is a naturally occurring copper complex with broad research applications
The trial did not resume enrollment Preclinical cardiac evidence: Animal models of myocardial infarction demonstrated RGN-352 reduced scar volume, improved cardiac function, and increased survival, forming the basis for the clinical program (PMID: 25015963) RGN-259 (Thymosin Beta-4 Ophthalmic Solution for Dry Eye): ARISE-1 and ARISE-2 Phase 3 trials: Evaluated Thymosin Beta-4 eye drops for dry eye disease with mixed results some endpoints showed improvement in signs of dry eye, but the pre-specified co-primary endpoints were not met, though some secondary endpoints showed statistically significant improvements in certain signs of dry eye (PMID: 23050815) These ophthalmic trials represent the most advanced clinical testing of any Thymosin Beta-4 formulation Independent Pilot Study (China, 2016): A small pilot study randomized 10 STEMI (heart attack) patients into two groups: 5 receiving Thymosin Beta-4-pretreated endothelial progenitor cells (EPCs) and 5 receiving untreated EPCs After 6 months, the Thymosin Beta-4-pretreated group showed trends toward improved cardiac function markers including ejection fraction and exercise capacity, though the very small sample size (n=5 per group) means these results should be considered hypothesis-generating only, not evidence of efficacy (PMID: 27288307) No severe complications were reported in either group during follow-up Important: This study used Thymosin Beta-4 as a cell pretreatment agent ex vivo (EPCs exposed to TB4 before transplantation), not as a directly administered drug
Clinical reviews 3 of peptide-based therapies suggest that, regarding the brain-gut axis, BPC 157 has neuroprotective and muscle-recovery properties
